1. Home
  2. Companies
  3. MSB
  4. Material Events

Mesoblast (ASX:MSB) — Material Events

ASX:MSB · 22 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 20 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
Mesoblast Secures Exclusive CAR Technology to Boost Cell Therapy PrecisionMedium
Mesoblast acquires exclusive CAR platform license to enhance MSC therapies for inflammatory diseases
15 Apr 2026 ·Acquisition Announcement ·85
Mesoblast Posts US$115M Ryoncil Revenue as Adult Trials and CAR Tech AdvanceMedium
Mesoblast reports US$115M Ryoncil revenue first year post-FDA, expands indications and advances trials
30 July 2026 ·Quarterly Activity and Cash Flow Report ·85
Mesoblast’s Ryoncil Sales Jump 66% After FDA Approval and CMS ReimbursementMedium
Mesoblast's Ryoncil Sales Surge 66% in Q2 Post FDA Approval and CMS J-Code
7 Oct 2025 ·Quarterly Revenue Announcement ·85
Mesoblast’s Ryoncil Sales Soar 60% as New $125M Facility Boosts GrowthMedium
Mesoblast's Ryoncil Sales Surge 60% in Q2 2025; Secures New $125M Facility
9 Jan 2026 ·Quarterly Sales and Financing Update ·85
Independent Study Finds Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHDMedium
Independent Study Shows Mesoblast's Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD Treatment
12 Dec 2025 ·Clinical Study Announcement ·85
Mesoblast Posts $48.7M Ryoncil Sales, Cuts Losses, Secures $125M Credit LineHigh
Mesoblast reports $48.7M Ryoncil sales, $40.2M loss, secures $125M credit facility, advances commercialization
27 Feb 2026 ·Form 6-K ·85
Mesoblast Secures FDA BLA Filing Number for Rexlemestrocel-L in End-Stage Heart FailureMedium
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L in End-Stage Heart Failure Patients with LVADs
1 July 2026 ·Regulatory Filing Announcement ·85
FDA Signals Support for Mesoblast’s Rexlemestrocel-L in Chronic Back Pain and Opioid ReductionHigh
FDA Feedback Supports Mesoblast's Rexlemestrocel-L Efficacy and Opioid Reduction in Chronic Back Pain
19 Jan 2026 ·Regulatory Update ·85
Mesoblast Hits 300-Patient Target in Phase 3 Trial for Back Pain TherapyMedium
Mesoblast completes patient target in Phase 3 trial for chronic low back pain
14 July 2026 ·Clinical Trial Milestone Announcement ·85
Mesoblast Completes Treatment in Pivotal Phase 3 Trial for Chronic Low Back PainMedium
Mesoblast completes patient treatment in pivotal Phase 3 trial for chronic low back pain
17 Aug 2026 ·Clinical Trial Update ·85
Mesoblast’s Ryoncil Achieves US$30.3M Q1 Sales, Nears US$100M Since LaunchMedium
Mesoblast's Ryoncil hits US$30.3M Q1 sales, nears US$100M since launch
7 Apr 2026 ·Quarterly Sales Update ·85
Mesoblast Reports US$30.3M Ryoncil Revenues and Advances Cell Therapy PipelineMedium
Mesoblast reports US$30.3M Ryoncil® revenues, achieves Phase 3 recruitment target, and advances cell therapy pipeline
30 Apr 2026 ·Quarterly Activity and Appendix 4C Cash Flow Report ·85
Mesoblast Prepares FDA Talks on Rexlemestrocel-L’s Opioid Cessation PromiseMedium
Mesoblast to meet FDA on rexlemestrocel-L Phase 3 opioid cessation data for chronic low back pain
5 Nov 2025 ·Regulatory Update ·85
Mesoblast’s Ryoncil Sales Surge 60% as New US$125M Credit Boosts GrowthMedium
Mesoblast reports 60% sales growth for Ryoncil, secures US$125M credit facility, advances clinical trials and FDA discussions
29 Jan 2026 ·Activity Report and Appendix 4C Quarterly Cash Flow Report ·85
Mesoblast Secures FDA Clearance to Launch Registrational Trial of Ryoncil in Duchenne Muscular DystrophyHigh
Mesoblast Gets FDA Clearance for Registrational Trial of Ryoncil in Duchenne Muscular Dystrophy
8 Apr 2026 ·Clinical Trial Announcement ·85
Mesoblast’s RYONCIL Surges with FDA Nod and $30M Quarterly RevenueMedium
Mesoblast's RYONCIL FDA-approved, strong launch; advancing pipeline and manufacturing scale-up
25 Nov 2025 ·Annual General Meeting Presentation ·85
Mesoblast’s Ryoncil® Surpasses US$115M Annual Revenue with Strong Pediatric DemandMedium
Mesoblast reports US$115M full-year revenue for Ryoncil® with strong growth outlook
10 July 2026 ·Financial Results ·85
Mesoblast’s Ryoncil Revenues Surge 69% Following Key FDA and CMS MilestonesHigh
Mesoblast’s Ryoncil revenues surge 69% in Q1 FY2026 post FDA and CMS milestones
20 Oct 2025 ·Quarterly Activity Report and Appendix 4C ·85
Mesoblast Projects 37% Revenue Surge on Ryoncil Sales in Q4 2025Medium
Mesoblast forecasts over US$30M Q4 revenue from Ryoncil, up 37% QoQ
25 Nov 2025 ·Trading Update ·80
Mesoblast Secures US$125M Credit Line, Slashes Debt Costs and Boosts FlexibilityMedium
Mesoblast secures US$125M lower-cost, non-dilutive five-year credit line to retire senior debt
30 Dec 2025 ·Debt Refinancing Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.